Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer

Lung cancer is one of the most common types of cancer that occurs in both men and women. This tumor is the leading cause of death from cancer, accounting for 18.4% of the total number of deaths. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all cases. Withi...

Full description

Saved in:
Bibliographic Details
Main Authors: O. N. Pavlova, O. P. Bukareva
Format: Article
Language:Russian
Published: Private institution educational organization of higher education "Medical University "ReaViz" 2024-04-01
Series:Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
Subjects:
Online Access:https://vestnik.reaviz.ru/jour/article/view/912
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849402696003485696
author O. N. Pavlova
O. P. Bukareva
author_facet O. N. Pavlova
O. P. Bukareva
author_sort O. N. Pavlova
collection DOAJ
description Lung cancer is one of the most common types of cancer that occurs in both men and women. This tumor is the leading cause of death from cancer, accounting for 18.4% of the total number of deaths. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all cases. Within its framework, adenocarcinoma (30-45%) and squamous cell carcinoma (25-40%) are most often found. Approximately 20% of patients living in the Russian Federation and suffering from non-small cell lung cancer have EGFR gene mutations. EGFR signaling pathways play an important role in the development of malignant tumors. They regulate cell cycle progression, influence apoptosis, stimulate the formation of new blood vessels and enhance the motility of cancer cells and their ability to metastasize. An in-depth understanding of the fundamental biology of rare EGFR mutations will help identify dependencies specific to these mutations. This knowledge can be used to develop therapeutic approaches targeting specific EGFR mutations and their impact on various pathologies. The results of these studies may help develop more precise and effective treatments that will specifically target specific EGFR mutations and their impact on various diseases.
format Article
id doaj-art-c712b5f93e844a8fac4c9becc0c44032
institution Kabale University
issn 2226-762X
2782-1579
language Russian
publishDate 2024-04-01
publisher Private institution educational organization of higher education "Medical University "ReaViz"
record_format Article
series Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
spelling doaj-art-c712b5f93e844a8fac4c9becc0c440322025-08-20T03:37:28ZrusPrivate institution educational organization of higher education "Medical University "ReaViz"Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье2226-762X2782-15792024-04-01141869010.20340/vmi-rvz.2024.1.CLIN.2570Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancerO. N. Pavlova0O. P. Bukareva1Samara State Medical UniversitySamara State Medical UniversityLung cancer is one of the most common types of cancer that occurs in both men and women. This tumor is the leading cause of death from cancer, accounting for 18.4% of the total number of deaths. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all cases. Within its framework, adenocarcinoma (30-45%) and squamous cell carcinoma (25-40%) are most often found. Approximately 20% of patients living in the Russian Federation and suffering from non-small cell lung cancer have EGFR gene mutations. EGFR signaling pathways play an important role in the development of malignant tumors. They regulate cell cycle progression, influence apoptosis, stimulate the formation of new blood vessels and enhance the motility of cancer cells and their ability to metastasize. An in-depth understanding of the fundamental biology of rare EGFR mutations will help identify dependencies specific to these mutations. This knowledge can be used to develop therapeutic approaches targeting specific EGFR mutations and their impact on various pathologies. The results of these studies may help develop more precise and effective treatments that will specifically target specific EGFR mutations and their impact on various diseases.https://vestnik.reaviz.ru/jour/article/view/912egfrnon-small cell lung cancer
spellingShingle O. N. Pavlova
O. P. Bukareva
Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье
egfr
non-small cell lung cancer
title Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
title_full Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
title_fullStr Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
title_full_unstemmed Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
title_short Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
title_sort detection of egfr gene mutations for prescription of targeted drugs for non small cell lung cancer
topic egfr
non-small cell lung cancer
url https://vestnik.reaviz.ru/jour/article/view/912
work_keys_str_mv AT onpavlova detectionofegfrgenemutationsforprescriptionoftargeteddrugsfornonsmallcelllungcancer
AT opbukareva detectionofegfrgenemutationsforprescriptionoftargeteddrugsfornonsmallcelllungcancer